Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

- PMLiVE

FREE Live Webinar – Solving your patient recruitment & retention challenges – 15th November 2023

Join Innovative Trials and Avillion in this FREE webinar

Innovative Trials

- PMLiVE

A New Era in Patient Recruitment & Retention

Innovative Trials launches ‘first of its kind’ service to boost clinical trial patient recruitment and retention .

Innovative Trials

- PMLiVE

Merck and Daiichi Sankyo announce ADC agreement worth up to $22bn

The companies will jointly develop and commercialise three of Daiichi Sankyo’s cancer candidates

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer trial

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

UCL study finds certain ethnicities experience greater effect of dementia risk factors

Researchers analysed health data from nearly one million adults in England

- PMLiVE

Launch excellence: five critical areas

By Jonathan Carney

- PMLiVE

New syndicated COPD report now available

Living with COPD 2023

Inizio

Increased Timeliness for yor Advisory Boards

We've broken down the top ten benefits of why virtual advisory boards are superior to in-person and hybrid advisory boards. #3. Increased Timeliness to Insight-gathering and Output Delivery Based on...

Impetus Digital

- PMLiVE

Medscape Medical Affairs Selected as Finalist for 2023 Pharmaceutical Market Excellence Awards (PMEAs)

We’re delighted to announce that two Global Medscape Medical Affairs programmes have been shortlisted in various categories for The Pharmaceutical Market Excellence Awards (PMEAs). The two programmes selected both succeeded...

Medscape Medical Affairs

- PMLiVE

Takeda announces EC approval for Adcetris combination in Hodgkin lymphoma

The ADC has been approved alongside doxorubicin, vinblastine and dacarbazine

- PMLiVE

Scientists discover way to reverse drug resistance in prostate cancer

Targeting ‘hijacked’ white blood cells could reverse drug resistance and slow tumour progression

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

Non-small cell lung cancer represents approximately 85% of all lung cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links